Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITGB2 neoantigen mRNA lipid nanoparticle vaccine
- Development stage
- Unknown
- Lead developer
- Sichuan Cancer Hospital
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The ITGB2 neoantigen mRNA lipid nanoparticle vaccine is an experimental cancer immunotherapy developed by Sichuan Cancer Hospital for the treatment of hepatocellular carcinoma (HCC). The vaccine utilizes mRNA encoding a neoantigen derived from the ITGB2 (Integrin Subunit Beta 2) protein, encapsulated within lipid nanoparticles (LNPs) for delivery. Its mechanism involves the expression of the ITGB2 neoantigen in dendritic cells to stimulate a specific immune response, particularly the activation of CD4+ T-cells. In clinical research, it is being evaluated for its ability to enhance the efficacy of PD-1 inhibitors by promoting an immunologically "hot" tumor microenvironment and increasing tumor-killing activity.
- Other names
- ITGB2 neoantigen vaccinationITGB-2 neoantigen vaccinationITGB 2 neoantigen vaccination
02
Targets
T-cell receptor specific for ITGB2-derived neoantigen peptide-MHC complexesIFIH1 (MDA5)TLR7/8 (Toll-like receptor 7 and Toll-like receptor 8)MHC class I/II presenting ITGB2-derived neoantigen peptides
Beyond the preview
Go deeper on ITGB2 neoantigen mRNA lipid nanoparticle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITGB2 neoantigen mRNA lipid nanoparticle vaccine.